Kiniksa Pharmaceuticals reports preliminary 2024 net product revenue of $416.4 million

More on Kiniksa Pharmaceutical

• Seeking Alpha’s Quant Rating on Kiniksa Pharmaceuticals
• Historical earnings data for Kiniksa Pharmaceuticals

Seeking Alpha | January 13, 2025

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours

Yahoo | January 6, 2025

Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has experienced a 3.5% drop, yet it has shown resilience with a 22% rise over the past year and an anticipated annual earnings growth of 15%. In this dynamic environment, identifying high-growth tech stocks involves assessing their potential to capitalize on technological advancements and market trends while aligning with robust growth forecasts.

Yahoo | December 20, 2024

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024 at 9:35 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 4

Yahoo | November 26, 2024

Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025?

We recently published a list of 10 Top Performing European Stocks Heading into 2025. In this article, we are going to take a look at where Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) stands against other top performing European stocks. As per Deloitte, inflation in the Eurozone slightly rebounded in October but was still quite low. The consumer […]

Yahoo | November 13, 2024

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024 at 12:00 p.m. Greenwich Mean Time (7:00 a.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’

Yahoo | November 12, 2024

Kiniksa Pharmaceuticals International, plc Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

It's been a mediocre week for Kiniksa Pharmaceuticals International, plc ( NASDAQ:KNSA ) shareholders, with the stock...

Yahoo | November 1, 2024

Kiniksa Pharmaceuticals International Third Quarter 2024 Earnings: EPS Misses Expectations

Kiniksa Pharmaceuticals International ( NASDAQ:KNSA ) Third Quarter 2024 Results Key Financial Results Revenue...

Yahoo | October 30, 2024

Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call

Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call

Yahoo | October 30, 2024

Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ...

Kiniksa Pharmaceuticals International PLC (KNSA) reports a 73% year-over-year revenue increase, raises full-year sales guidance, and continues to expand its prescriber base.

Yahoo | October 30, 2024